Rege Nephro

Rege Nephro announced ~$10.6M in J-KISS Financing financing on July 21, 2026. Rege Nephro closed approximately $10.6 million through J-KISS share acquisition rights from 13 investors to advance RN-014 and RN-032 for kidney disease.

Round details

The financing includes backing from JAFCO Group Co., Ltd., JIC Venture Growth Investments Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., SPARX Asset Management Co., Ltd., Kyoto University Innovation Capital Co., Ltd., Chushin Venture Capital Co., Ltd., BA7 Venture Capital CORP, DCI Partners Co., Ltd.. The company did not publish a valuation with the announcement.

• Round: J-KISS Financing
• Capital announced: ~$10.6M

How the company plans to use the capital

Rege Nephro said the proceeds will support RN-014 commercialization and global licensing and partnering activities, nonclinical development of RN-032, and continued discovery and translational research. The company also plans to hire scientific, clinical development, and business development staff.

Why this matters for GTM teams

The company said the financing is intended to support its growth through its anticipated Series C financing and beyond.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Rege Nephro J-KISS financing announcement.